Guselkumab meets primary endpoints in phase 3 psoriatic arthritis program

Johnson & Johnson’s Janssen Pharmaceutical said that its IL-23 p19 inhibitor TREMFYA (guselkumab) met the primary endpoints of American College of Rheumatology 20% improvement (ACR20) ... Read More